Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

Nature Biotechnology volume 27, pages 77–83 (2009)Cite this article

Abstract

The aberrant activation of tyrosine kinases represents an important oncogenic mechanism, and yet the majority of such events remain undiscovered. Here we describe a bead-based method for detecting phosphorylation of both wild-type and mutant tyrosine kinases in a multiplexed, high-throughput and low-cost manner. With the aim of establishing a tyrosine kinase–activation catalog, we used this method to profile 130 human cancer lines. Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo. Testing of dasatinib-resistant tyrosine kinase alleles confirmed that SRC is indeed the relevant target of dasatinib, which inhibits many tyrosine kinases. These studies establish the feasibility of tyrosine kinome–wide phosphorylation profiling and point to SRC as a possible therapeutic target in glioblastoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Luminex immunosandwich assay and IP-MS approach.
Figure 2: Luminex screen identifies activated tyrosine kinases in human cancer cell lines and primary glioblastomas.
Figure 3: Dasatinib effectively blocked tumor progression in vitro and in vivo, and resistant mutants of SRC and FYN rescued dasatinib effects in glioma cells.

Similar content being viewed by others

Accession codes

Accessions

Gene Expression Omnibus

References

  1. Simon, M.P. et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15, 95–98 (1997).

    Article  CAS  PubMed  Google Scholar 

  2. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007–20012 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Heisterkamp, N., Stam, K., Groffen, J., de Klein, A. & Grosveld, G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315, 758–761 (1985).

    Article  CAS  PubMed  Google Scholar 

  4. Tuveson, D.A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001).

    Article  CAS  PubMed  Google Scholar 

  5. Smolen, G.A. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA 103, 2316–2321 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nakamura, Y. et al. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci. 99, 14–22 (2008).

    Article  CAS  PubMed  Google Scholar 

  7. Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Kita, Y.A. et al. NDF/heregulin stimulates the phosphorylation of Her3/erbB3. FEBS Lett. 349, 139–143 (1994).

    Article  CAS  PubMed  Google Scholar 

  9. Ueda, T. et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res. 59, 6080–6086 (1999).

    CAS  PubMed  Google Scholar 

  10. Desbois-Mouthon, C. et al. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 36, 1528–1536 (2002).

    Article  CAS  PubMed  Google Scholar 

  11. Tibes, R. et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512–2521 (2006).

    Article  CAS  PubMed  Google Scholar 

  12. Vescovi, A.L., Galli, R. & Reynolds, B.A. Brain tumour stem cells. Nat. Rev. Cancer 6, 425–436 (2006).

    Article  CAS  PubMed  Google Scholar 

  13. Libermann, T.A. et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144–147 (1985).

    Article  CAS  PubMed  Google Scholar 

  14. Sugawa, N., Ekstrand, A.J., James, C.D. & Collins, V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 87, 8602–8606 (1990).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

  16. Lombardo, L.J. et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004).

    Article  CAS  PubMed  Google Scholar 

  17. Parsons, S.J. & Parsons, J.T. Src family kinases, key regulators of signal transduction. Oncogene 23, 7906–7909 (2004).

    Article  CAS  PubMed  Google Scholar 

  18. Angers-Loustau, A., Hering, R., Werbowetski, T.E., Kaplan, D.R. & Del Maestro, R.F. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res. 2, 595–605 (2004).

    CAS  PubMed  Google Scholar 

  19. Lund, C.V. et al. Reduced glioma infiltration in Src-deficient mice. J. Neurooncol. 78, 19–29 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Park, C.M. et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 66, 8511–8519 (2006).

    Article  CAS  PubMed  Google Scholar 

  21. Phuong, L.K. et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63, 2462–2469 (2003).

    CAS  PubMed  Google Scholar 

  22. Carter, T.A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102, 11011–11016 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).

    Article  CAS  PubMed  Google Scholar 

  24. Shah, N.P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).

    Article  CAS  PubMed  Google Scholar 

  25. Feinstein, A.R. Principles of Medical Statistics (Chapman & Hall / CRC Boca Raton, FL, 2002).

    Google Scholar 

  26. Efron, B. Nonparametric standard errors and confidence intervals. Can. J. Stat. 9, 139–158 (1981).

    Article  Google Scholar 

  27. Rush, J. et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94–101 (2005).

    Article  CAS  PubMed  Google Scholar 

  28. Rubin, J.B. et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. USA 100, 13513–13518 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Levi Garraway and Johnathan Fletcher for cell lines. We thank Julie Dang for her technical support on the pY419SRC IHC experiment. J.D. is supported by a fellowship from the Leukemia and Lymphoma Society and The Irving Family. I.K.M. is funded by the Brain Tumor Funders' Collaborative. The project has been funded in part with funds from the National Cancer Institute's (NCI) Initiative for Chemical Genetics, National Institutes of Health, under contract no. N01-CO-12400, and through the NCI's Integrative Cancer Biology Program.

Author information

Authors and Affiliations

  1. The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, 02142, Massachusetts, USA

    Jinyan Du, Paula Bernasconi, Karl R Clauser, D R Mani, Rameen Beroukhim, Melissa Burns, Bina Julian, Xiao P Peng, Haley Hieronymus, Rebecca L Maglathlin, Timothy A Lewis, Steven A Carr & Todd R Golub

  2. Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, 02115, Massachusetts, USA

    Jinyan Du, Paula Bernasconi, Melissa Burns, Haley Hieronymus, Andrew L Kung & Todd R Golub

  3. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, 02115, Massachusetts, USA

    Stephen P Finn, Rameen Beroukhim & Massimo Loda

  4. Howard Hughes Medical Institute, Chevy Chase, 20815, Maryland, USA

    Bina Julian, Xiao P Peng & Todd R Golub

  5. Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, 90095, California, USA

    Linda M Liau

  6. Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, 90095, California, USA

    Phioanh Nghiemphu

  7. Department of Neurology, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, 10021, New York, USA

    Ingo K Mellinghoff

  8. Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA

    David N Louis

Authors
  1. Jinyan Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula Bernasconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karl R Clauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D R Mani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen P Finn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rameen Beroukhim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melissa Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bina Julian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiao P Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Haley Hieronymus
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rebecca L Maglathlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Timothy A Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Linda M Liau
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Phioanh Nghiemphu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ingo K Mellinghoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. David N Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Massimo Loda
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Steven A Carr
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Andrew L Kung
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Todd R Golub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Todd R Golub.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–3, Methods (PDF 288 kb)

Supplementary Table 1

Tyrosine phosphorylated proteins identified with IP-MS method in five cancer cell lines. (XLS 36 kb)

Supplementary Table 2

Capture antibodies and positive control samples used in Luminex immunosandwich assay. (XLS 35 kb)

Supplementary Table 3

Tyrosine phosphorylation levels on antibody validation samples. (XLS 75 kb)

Supplementary Table 4

Tyrosine phosphorylation levels of wild-type and dasatinib-resistant tyrosine kinase mutants measured by Luminex assay. (XLS 48 kb)

Supplementary Table 5

Tyrosine phosphorylation levels in six cell lines used for measuring technical and biological variations. (XLS 194 kb)

Supplementary Table 6

Tyrosine phosphorylation levels on cancer cell lines. (XLS 91 kb)

Supplementary Table 7

Tyrosine phosphorylation levels and genomic data on the primary glioma samples. (XLS 26 kb)

Supplementary Table 8

pY419SRC immunohistochemsitry on primary GBM tissue microarrays. (XLS 22 kb)

Supplementary Table 9

Dasatinib EC50 and SRC phosphorylation levels in cancer cell lines. (XLS 28 kb)

Supplementary Table 10

ORF amplification and mutagenesis primers for generating dasatinib-resistant mutants. (XLS 24 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Du, J., Bernasconi, P., Clauser, K. et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27, 77–83 (2009). https://doi.org/10.1038/nbt.1513

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1513

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing